Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FAAH | O00519 | 9/20 | 0.56 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.53 |
| ▸ | EPAS1 | Q99814 | 2/20 | 0.53 |
| ▸ | PRKAB2 | O43741 | 4/20 | 0.51 |
| ▸ | PRKAG1 | P54619 | 4/20 | 0.51 |
| ▸ | PRKAA2 | P54646 | 4/20 | 0.51 |
| ▸ | PRKAA1 | Q13131 | 4/20 | 0.51 |
| ▸ | PRKAG3 | Q9UGI9 | 4/20 | 0.51 |
| ▸ | PRKAG2 | Q9UGJ0 | 4/20 | 0.51 |
| ▸ | PRKAB1 | Q9Y478 | 4/20 | 0.51 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.51 |
| ▸ | SLC2A1 | P11166 | 2/20 | 0.48 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.47 |
| ▸ | KIT | P10721 | 2/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19970830 | 0.94 | FAAH (0.56) | FAAHHIF1AEPAS1PRKAB2PRKAG1 | |
| SCHEMBL19970727 | 0.91 | FAAH (0.63) | FAAHHIF1AEPAS1PRKAB2PRKAG1 | |
| SCHEMBL19970867 | 0.90 | FAAH (0.54) | FAAHCYP2D6KIT | |
| SCHEMBL19970797 | 0.87 | DGAT1 (0.53) | HIF1AEPAS1SLC2A1KIT | |
| SCHEMBL32660769 | 0.85 | FAAH (0.57) | FAAHHIF1AEPAS1PRKAB2PRKAG1 | |
| SCHEMBL19970861 | 0.85 | FAAH (0.57) | FAAHHIF1AEPAS1PRKAB2PRKAG1 | |
| SCHEMBL19970736 | 0.85 | SIGMAR1 (0.52) | HIF1AEPAS1PRKAB2PRKAG1PRKAA2 | |
| SCHEMBL19970728 | 0.84 | FAAH (0.63) | FAAHHIF1AEPAS1PRKAB2PRKAG1 | |
| SCHEMBL19970868 | 0.83 | ALDH1A1 (0.55) | FAAHKIT | |
| SCHEMBL19970798 | 0.80 | KCNH2 (0.62) | HIF1AEPAS1SLC2A1KIT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11479571-B2 | Benzimidazol derivatives for treating filovirus infection | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) | 2022-10-25 | — | — | US | disclosed |
| US-20210292350-A1 | BENZIMIDAZOL DERIVATIVES FOR TREATING FILOVIRUS INFECTION | UNIVERSITE D'ORLEANS (FR) | 2021-09-23 | — | — | US | disclosed |
| EP-3296297-A1 | BENZIMIDAZOL DERIVATIVES FOR TREATING FILOVIRUS INFECTION | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) | 2018-03-21 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210292350-A1 | BENZIMIDAZOL DERIVATIVES FOR TREATING FILOVIRUS INFECTION | FIP1L1, ZC3HAV1, MAVS | FAAH 3154/4885HIF1A 3621/4885EPAS1 3323/4885 |
| US-11479571-B2 | Benzimidazol derivatives for treating filovirus infection | FIP1L1, ZC3HAV1, MAVS | FAAH 3154/4885HIF1A 3621/4885EPAS1 3323/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.